两例滤泡性淋巴瘤患者在接受苯达莫司汀和奥滨尤妥珠单抗或利妥昔单抗治疗后出现持续性 SARS-CoV-2 感染和多次临床复发。
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
机构信息
Infectious Disease Unit, Azienda Ospedaliera Universitaria di Modena, Largo del Pozzo 71, 41124, Modena, Italy.
Hematology Unit and Chair, Azienda Ospedaliera Universitaria di Modena, Modena, Italy.
出版信息
Infection. 2023 Oct;51(5):1577-1581. doi: 10.1007/s15010-023-02039-2. Epub 2023 Apr 19.
Abstract
PURPOSE
People with hematologic malignancies have a significantly higher risk of developing severe and protracted forms of SARS-CoV-2 infection compared to immunocompetent patients, regardless of vaccination status.
RESULTS
We describe two cases of prolonged SARS-CoV-2 infection with multiple relapses of COVID-19 pneumonia in patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab. The aim is to highlight the complexity of SARS-CoV-2 infection in this fragile group of patients and the necessity of evidence-based strategies to treat them properly.
CONCLUSIONS
Patients with hematological malignancies treated with bendamustine and anti-CD20 antibodies had a significant risk of prolonged and relapsing course of COVID-19. Specific preventive and therapeutic strategies should be developed for this group of patients.
摘要
目的
与免疫功能正常的患者相比，血液系统恶性肿瘤患者罹患严重和持久的 SARS-CoV-2 感染的风险显著更高，无论其疫苗接种状态如何。
结果
我们描述了两例滤泡性淋巴瘤患者在接受苯达莫司汀和奥滨尤妥珠单抗或利妥昔单抗治疗后，SARS-CoV-2 感染持续时间延长且 COVID-19 肺炎多次复发的病例。目的是强调在这群脆弱的患者中 SARS-CoV-2 感染的复杂性，以及制定基于证据的策略来对其进行适当治疗的必要性。
结论
接受苯达莫司汀和抗 CD20 抗体治疗的血液系统恶性肿瘤患者 COVID-19 呈显著延长和复发病程的风险。应针对这群患者制定特定的预防和治疗策略。
相似文献
1
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.两例滤泡性淋巴瘤患者在接受苯达莫司汀和奥滨尤妥珠单抗或利妥昔单抗治疗后出现持续性 SARS-CoV-2 感染和多次临床复发。
Infection. 2023 Oct;51(5):1577-1581. doi: 10.1007/s15010-023-02039-2. Epub 2023 Apr 19.
2
Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma.免疫功能低下患者在接受奥滨尤妥珠单抗联合苯达莫司汀治疗滤泡性淋巴瘤后出现持续 COVID-19。
Intern Med. 2022 Aug 15;61(16):2523-2526. doi: 10.2169/internalmedicine.9136-21. Epub 2022 May 31.
3
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.在 GADOLIN Ⅲ期研究中，评估奥滨尤妥珠单抗在利妥昔单抗难治性滤泡淋巴瘤患者中的药代动力学、暴露量、疗效和安全性。
Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12.
4
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.抗 CD20 抗体和苯达莫司汀可减弱 B 细胞非霍奇金淋巴瘤患者对 COVID-19 疫苗的体液免疫反应。
Ann Hematol. 2023 Jun;102(6):1421-1431. doi: 10.1007/s00277-023-05204-7. Epub 2023 Apr 12.
5
Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma-affected patients.苯达莫司汀削弱了利妥昔单抗治疗的 B 细胞淋巴瘤患者对 SARS-CoV-2 疫苗接种的体液但不细胞免疫。
Front Immunol. 2023 Dec 1;14:1322594. doi: 10.3389/fimmu.2023.1322594. eCollection 2023.
6
Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma.奥妥珠单抗联合减量苯达莫司汀对老年滤泡性淋巴瘤患者有效。
Ann Hematol. 2023 Jan;102(1):243-244. doi: 10.1007/s00277-022-05037-w. Epub 2022 Nov 11.
7
Prolonged SARS-CoV-2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: A case report.在使用奥妥珠单抗和苯达莫司汀治疗滤泡性淋巴瘤期间出现的新型冠状病毒2型（SARS-CoV-2）长期感染：一例报告
Clin Case Rep. 2023 Aug 28;11(9):e7861. doi: 10.1002/ccr3.7861. eCollection 2023 Sep.
8
Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.在美国，对于接受含利妥昔单抗方案治疗后复发或难治的滤泡性淋巴瘤患者，奥妥珠单抗联合苯达莫司汀继以奥妥珠单抗单药治疗的成本效益分析
J Med Econ. 2018 Oct;21(10):960-967. doi: 10.1080/13696998.2018.1489254. Epub 2018 Jul 6.
9
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.奥滨尤妥珠单抗联合苯达莫司汀对比苯达莫司汀单药治疗利妥昔单抗难治性惰性非霍奇金淋巴瘤（GADOLIN）：一项随机、对照、开放标签、多中心、3 期临床试验。
Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23.
10
Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.奥滨尤妥珠单抗联合苯达莫司汀序贯奥滨尤妥珠单抗维持治疗与苯达莫司汀单药治疗在挪威利妥昔单抗难治滤泡性淋巴瘤患者中的成本效果分析。
Appl Health Econ Health Policy. 2018 Aug;16(4):569-577. doi: 10.1007/s40258-018-0401-y.
引用本文的文献
1
Fatal SARS-CoV-2 Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia.严重再生障碍性贫血异基因造血干细胞移植后致命的新型冠状病毒 2 型再激活
Cureus. 2025 Jul 1;17(7):e87084. doi: 10.7759/cureus.87084. eCollection 2025 Jul.
2
Clinical and molecular landscape of prolonged SARS-CoV-2 infection with resistance to remdesivir in immunocompromised patients.免疫功能低下患者中对瑞德西韦耐药的新型冠状病毒2（SARS-CoV-2）持续感染的临床和分子特征
PNAS Nexus. 2025 Mar 18;4(4):pgaf085. doi: 10.1093/pnasnexus/pgaf085. eCollection 2025 Apr.
3
Clinical Features of Patients with COVID-19 Recurrence During Hospitalization in the Omicron Variant Surge.奥密克戎变异株激增期间住院的新冠病毒感染复发患者的临床特征
Infect Drug Resist. 2024 Nov 11;17:5011-5015. doi: 10.2147/IDR.S485976. eCollection 2024.
4
Clinical Features and Prognosis of Patients with COVID-19 and B-Cell Non-Hodgkin Lymphoma.新型冠状病毒肺炎合并B细胞非霍奇金淋巴瘤患者的临床特征与预后
Infect Drug Resist. 2024 Oct 17;17:4501-4510. doi: 10.2147/IDR.S477107. eCollection 2024.
5
COVID-19-related Pneumonitis in Immunocompromised Patients: Reviewing Clinical Features and Management Approaches.免疫功能低下患者的新型冠状病毒肺炎相关肺炎：临床特征与管理方法综述
J Community Hosp Intern Med Perspect. 2024 Sep 9;14(5):63-72. doi: 10.55729/2000-9666.1399. eCollection 2024.
6
Infectious Disease Prophylaxis During and After Immunosuppressive Therapy.免疫抑制治疗期间及之后的传染病预防
Kidney Int Rep. 2024 Apr 25;9(8):2337-2352. doi: 10.1016/j.ekir.2024.04.043. eCollection 2024 Aug.
7
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.对于新诊断的晚期滤泡性淋巴瘤的接种疫苗患者，暴露于奥妥珠单抗并不影响其感染SARS-CoV-2的结果。
Br J Haematol. 2024 Dec;205(6):2219-2227. doi: 10.1111/bjh.19661. Epub 2024 Jul 22.
8
The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody.评估在接受抗 CD20 抗体治疗的 B 细胞淋巴瘤 COVID-19 患者中，使用抗 SARS-CoV-2 单克隆抗体和长期使用抗病毒药物期间，病毒持续脱落的风险因素。
BMC Infect Dis. 2024 Jul 22;24(1):715. doi: 10.1186/s12879-024-09631-3.
9
Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical ventilation and mortality in seronegative and seropositive patients.奥密克戎时代血液系统恶性肿瘤患者的严重急性呼吸综合征冠状病毒2感染：血清阴性和血清阳性患者的呼吸衰竭、机械通气需求及死亡率
EJHaem. 2024 Apr 9;5(3):505-515. doi: 10.1002/jha2.867. eCollection 2024 Jun.
10
COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?2019冠状病毒病及其合并症：代谢组学揭示了什么？
Metabolites. 2024 Mar 30;14(4):195. doi: 10.3390/metabo14040195.
本文引用的文献
1
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review.奥滨尤妥珠单抗治疗 B 细胞恶性肿瘤：全面综述。
Future Oncol. 2022 Aug;18(26):2943-2966. doi: 10.2217/fon-2022-0112. Epub 2022 Jul 20.
2
Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case-control study.与非血液系统恶性肿瘤患者相比，血液系统恶性肿瘤患者的 2019 冠状病毒病临床病程的呼吸恶化时间更长：一项病例对照研究的结果。
Infection. 2022 Oct;50(5):1373-1382. doi: 10.1007/s15010-022-01869-w. Epub 2022 Jul 3.
3
Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19.对于被诊断感染奥密克戎变异株新冠病毒的血液学患者，使用奥妥珠单抗治疗会导致更差的预后。
Br J Haematol. 2022 Sep;198(5):826-829. doi: 10.1111/bjh.18315. Epub 2022 Jun 19.
4
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.替沙格韦单抗-西加韦单抗肌内注射用于 COVID-19 早期门诊治疗的疗效和安全性（TACKLE）：一项 3 期、随机、双盲、安慰剂对照试验。
Lancet Respir Med. 2022 Oct;10(10):985-996. doi: 10.1016/S2213-2600(22)00180-1. Epub 2022 Jun 7.
5
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.新冠疫苗在免疫功能低下患者中的有效性：系统评价和荟萃分析。
BMJ. 2022 Mar 2;376:e068632. doi: 10.1136/bmj-2021-068632.
6
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
7
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.免疫功能低下的成人血液病患者中 mRNA-1273 COVID-19 疫苗接种反应的定量分析。
Blood Adv. 2022 Mar 8;6(5):1537-1546. doi: 10.1182/bloodadvances.2021006917.
8
The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study.一名免疫功能低下患者体内存活的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）最长持续时间、病毒血症复发及复发性有症状冠状病毒病2019（COVID-19）——病例报告
Open Forum Infect Dis. 2021 Apr 28;8(11):ofab217. doi: 10.1093/ofid/ofab217. eCollection 2021 Nov.
9
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.抗CD20单克隆抗体对B细胞非霍奇金淋巴瘤患者接种BNT162b2疫苗血清学反应的影响
Leukemia. 2022 Feb;36(2):588-590. doi: 10.1038/s41375-021-01418-8. Epub 2021 Sep 20.
10
Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies.血液系统恶性肿瘤患者接种mRNA抗SARS-CoV-2疫苗后血清转化率低。
Leuk Lymphoma. 2021 Dec;62(13):3308-3310. doi: 10.1080/10428194.2021.1957877. Epub 2021 Jul 26.
Zotero 插件